Home › Myelofibrosis › NCT01973881

Quantitative MRI for Myelofibrosis

Quantitative MRI for Myelofibrosis - MRI Parameters as Biomarkers for Analyzing Extent of Disease and Measuring Response to Treatment

Who can join

Ages 18 to 99 · All sexes

Inclusion Criteria:

1. Male /female subjects over the age of 18
2. Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.
3. No contraindications to MRI
4. Able to undergo MRI without anesthesia

   \-

Exclusion Criteria:

1. Patients with pacemakers or other implanted magnetic devices that may malfunction or move because of the strong magnetic field inside the MRI room and scanner.
2. Any prior adverse event associated with MRI that is not related to injection of contrast agents or other medicines.

   \-

About the study

This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.

What is being tested

• T1 Weighted MRI (magnetic resonance imaging) (procedure)

Sponsor: University of Michigan Rogel Cancer Center · Participants: 192 · Started: Dec 22, 2014

Contact the study team

• Gary Luker, M.D. · Phone: 734-763-5476

Official record on ClinicalTrials.gov — NCT01973881

Locations in the U.S.

Conditions

• Myelofibrosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.